# PT-141 Research: Mechanism, Clinical Trials, and Published Findings > PT-141 (bremelanotide) research across 43 clinical trials: MC4R mechanism, RECONNECT Phase 3 HSDD data, Phase 2 ED findings, and 2022-2025 neuroimaging studies. Cited from the primary literature. ## The Research Record on PT-141 (Bremelanotide) PT-141 has one of the most thoroughly documented research profiles of any peptide compound studied for sexual dysfunction. The bremelanotide clinical development program enrolled approximately 3,500 subjects across 43 studies — from Phase 1 pharmacokinetic work in the early 2000s through the pivotal Phase 3 RECONNECT trials that supported FDA approval in 2019 [9]. ## PT-141 Mechanism of Action: Melanocortin Receptor Agonism PT-141 mechanism of action is defined by its selectivity for the melanocortin receptor family — specifically MC3R and MC4R. MC4R is concentrated in the medial preoptic area (mPOA) of the hypothalamus, a region central to sexual motivation and behavior. Activation of MC4R enhances presynaptic dopamine release in hypothalamic circuits, modulating the excitatory-inhibitory neurotransmitter balance that governs sexual desire [15]. HSDD is characterized by an imbalance of excitatory and inhibitory neurotransmitter levels in the brain's arousal circuits — dopamine and norepinephrine are the excitatory drivers; serotonin and endorphins the inhibitory. Approximately 10% of American women are affected by HSDD [15]. Bremelanotide addresses this imbalance upstream, at the receptor that initiates desire signaling. Early animal evidence established the hypothalamic locus precisely. Peripheral or direct mPOA infusion of bremelanotide in female rats dramatically and selectively increased solicitation behaviors without affecting lordosis or pacing — demonstrating that MC4R in the mPOA is the critical node for appetitive (desire-initiation) rather than consummatory sexual behavior [10]. ### PT-141 as a Melanocortin Receptor Agonist Melanocortin receptors are a family of five G-protein-coupled receptors (MC1R-MC5R) that respond to endogenous melanocortin peptides including alpha-MSH. PT-141 is a non-selective melanocortin receptor agonist with primary activity at MC3R and MC4R, and secondary activity at MC1R at higher doses. MC4R activation is held responsible for the pro-sexual effects; MC1R activation at high-frequency doses underlies the hyperpigmentation adverse event [9, 11]. A 2023 mouse study using Sim1-neuron-specific MC4R restoration in knockout animals demonstrated that MC4R signaling in Sim1 hypothalamic neurons is sufficient to restore normal sexual receptivity — independent of obesity, indicating separate sexual and metabolic melanocortin pathways [18]. ## Early Research Directions for PT-141 PT-141's research history begins with melanotan II — a synthetic alpha-MSH analogue developed for tanning — which incidentally produced pro-erectile effects in early self-administration reports. Investigation of melanotan II's active metabolite yielded PT-141, a cyclic peptide with greater selectivity and a cleaner pharmacokinetic profile. Neuroimaging work using c-Fos immunoreactivity in rat hypothalami confirmed central activation was the mechanism rather than peripheral vascular effects [12]. ## PT-141 and Hypoactive Sexual Desire Disorder in Women The RECONNECT program — two identically designed Phase 3 randomized double-blind placebo-controlled trials (NCT02333071, NCT02338960) — enrolled 1,202 premenopausal women with acquired, generalized HSDD of at least 6 months' duration. Both co-primary endpoints were achieved: statistically significant increases in satisfying sexual events per month and reductions in FSDS-DAO distress scores versus placebo [5]. Response rates were approximately 58% for bremelanotide versus 36% for placebo. Subgroup analyses confirmed that efficacy was consistent across age, weight, BMI, HSDD duration, and contraceptive status [5]. A 52-week open-label extension demonstrated sustained improvement through 76 weeks total exposure, with no new safety signals [14]. A single-dose Phase 2 study in 18 premenopausal women with sexual arousal disorder using 20 mg intranasal bremelanotide demonstrated significantly increased subjective sexual desire and arousal satisfaction versus placebo, with vaginal vasocongestion unchanged — indicating the compound's primary effect is on central desire rather than peripheral vasocongestion [3]. The Phase 2b dose-ranging study (bremelanotide 0.75, 1.25, 1.75 mg SC) demonstrated that 1.75 mg achieved statistically significant improvements across all 7 pre-specified endpoints (p≤0.03), establishing the dose for Phase 3 registration [13]. ## PT-141 Research in Male Sexual Dysfunction Phase 2 data in men provides substantial evidence of PT-141's erectogenic activity via central pathway activation, even in the absence of a completed Phase 3 program. Intranasal PT-141 at doses above 7 mg produced statistically significant erectile responses versus placebo in healthy males and men with mild-to-moderate ED, with onset approximately 30 minutes post-administration. No maximum tolerated dose was reached in the tested range [1]. Subcutaneous PT-141 at 1–6 mg demonstrated dose-dependent erectile responses in healthy males and men with inadequate response to sildenafil — both 4 mg and 6 mg SC doses showed statistically significant improvements in sildenafil non-responders [2]. PT-141 is not FDA-approved for erectile dysfunction or any male indication. ## PT-141 vs. PDE-5 Inhibitors: Mechanism Comparison PT-141 acts centrally on melanocortin receptors in the CNS to modulate desire and arousal initiation, while PDE-5 inhibitors act peripherally on vascular smooth muscle. Studies show PT-141 can produce responses in subjects who did not respond to sildenafil [2], demonstrating that the central pathway remains functional even when the peripheral vascular response is insufficient. PT-141 does not carry the hypotensive effects associated with PDE-5 inhibitors — ambulatory blood pressure monitoring showed transient systolic increases (not reductions) at the 1.75 mg clinical dose [8]. ## Neuroimaging Evidence: How PT-141 Alters Brain Processing The first neuroimaging study of bremelanotide's effects on brain processing of erotic stimuli — conducted at Imperial College London in women with HSDD — used fMRI to characterize changes following 1.75 mg SC administration [17]. The key findings: (1) increased cerebellar and supplementary motor area activity, (2) deactivation of the secondary somatosensory cortex (reduced excessive self-monitoring), and (3) enhanced amygdala-insula functional connectivity. The pattern supports the top-down inhibition theory of HSDD pathophysiology [17]. A 2025 animal study in female Syrian hamsters found that bremelanotide did not affect melanocortin receptor mRNA expression in the mesolimbic dopamine VTA-NAc reward circuit, consistent with the mPOA hypothalamic circuits being the primary locus of action [21]. ## Research-Documented Effects of PT-141 Across the preclinical and clinical literature, PT-141 has demonstrated: - Pro-erectile activity in rat, nonhuman primate, and human subjects [12] - Selective increase in appetitive sexual behaviors in rat models [10, 16] - Increased subjective sexual desire and arousal satisfaction in women with sexual arousal disorder [3] - Statistically significant improvements in satisfying sexual events and distress measures in two Phase 3 HSDD trials [5] - Dose-dependent erectile responses in PDE-5 non-responders [2] - Altered brain processing of erotic stimuli consistent with reduced self-monitoring [17] ## References [1] Diamond LE, et al. Double-blind evaluation of intranasal PT-141. Int J Impotence Research. 2004. https://pubmed.ncbi.nlm.nih.gov/14963471/ [2] Rosen RC, et al. Evaluation of subcutaneous PT-141. Int J Impotence Research. 2004. https://pubmed.ncbi.nlm.nih.gov/14999221/ [3] Diamond LE, et al. Effect on subjective sexual response in women with sexual arousal disorder. Journal of Sexual Medicine. 2006. https://pubmed.ncbi.nlm.nih.gov/16839319/ [5] Simon JA, et al. RECONNECT Phase 3 subgroup analyses. Journal of Women's Health. 2022. https://pubmed.ncbi.nlm.nih.gov/35230162/ [8] White WB, et al. Ambulatory blood pressure monitoring for bremelanotide. Journal of Hypertension. 2017. https://pubmed.ncbi.nlm.nih.gov/27977473/ [9] Clayton AH, et al. Safety Profile of Bremelanotide. Journal of Women's Health. 2022. https://pubmed.ncbi.nlm.nih.gov/35147466/ [10] Pfaus J, et al. Bremelanotide: preclinical CNS effects. Journal of Sexual Medicine. 2007. https://pubmed.ncbi.nlm.nih.gov/17958619/ [11] Shadiack AM, et al. Melanocortins in male and female sexual dysfunction. Current Topics in Medicinal Chemistry. 2007. https://pubmed.ncbi.nlm.nih.gov/17584134/ [12] Molinoff PB, et al. PT-141: a melanocortin agonist for sexual dysfunction. NYAS. 2003. https://pubmed.ncbi.nlm.nih.gov/12851303/ [13] Althof S, et al. Responder Analyses from Phase 2b dose-ranging study. Journal of Sexual Medicine. 2019. https://pubmed.ncbi.nlm.nih.gov/31277966/ [14] Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide. Obstetrics and Gynecology. 2019. https://pubmed.ncbi.nlm.nih.gov/31599847/ [15] Pfaus JG, et al. Neurobiology of bremelanotide for HSDD. CNS Spectrums. 2022. https://pubmed.ncbi.nlm.nih.gov/33455598/ [16] Pfaus JG, et al. Selective facilitation of sexual solicitation in female rat. PNAS. 2004. https://pubmed.ncbi.nlm.nih.gov/15226502/ [17] Thurston L, et al. MC4R agonism enhances sexual brain processing in women with HSDD. JCI. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9525110/ [18] Semple EA, et al. MC4R signaling in Sim1 neurons. Frontiers in Endocrinology. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10080118/ [21] Borland JM, et al. Female Syrian hamster analyses of bremelanotide. Neuropharmacology. 2025. https://pubmed.ncbi.nlm.nih.gov/39793696/ --- Coin-operated reading room for the bremelanotide literature — every trial catalogued, no clinical service rendered.